Skip to main content
Clinical Trials/EUCTR2006-002295-18-DK
EUCTR2006-002295-18-DKActive, not recruitingNot Applicable

ACT: Avastin and Chemotherapy followed by Avastin alone or in combination with Tarceva for the treatment of metastatic colorectal cancer - ACT

niversity Hospital, Dept of Oncology, clinical trial unit0 sites182 target enrollmentStarted: December 13, 2006Last updated:
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
182

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Untreated metastatic colorectal carcinoma
  • Age = 18 years
  • Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST) criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Life expectancy more than 3 months
  • Adequate haematological, renal and liver function
  • Blood sample and paraffin embedded tumour tissue for translational research
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • Adjuvant therapy within 6 months
  • Central nervous system (CNS) metastases
  • Clinically significant atherosclerotic vascular disease

Investigators

Sponsor
niversity Hospital, Dept of Oncology, clinical trial unit

Similar Trials

Active, not recruiting
Not Applicable
ACT: Avastin and Chemoterapy followed by Avastin alone or in combination with Tarceva for the treatment of metatstatic colorectal cancer - ACT
EUCTR2006-002295-18-SEniversity Hospital Lund, Dept of Oncology, Clinical Trial Unit240
Active, not recruiting
Phase 1
Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer - ACT2Patients with previously untreated metastatic colorectal carcinoma.MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-019815-40-DKSkåne University Hospital, Department of Oncology230
Active, not recruiting
Not Applicable
Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancerPatients with previously untreated metastatic colorectal carcinoma.MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-019815-40-SESkåne University Hospital, Department of Oncology230
Completed
Phase 4
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited MetastasesColorectal Neoplasms
NCT01972490Xu jianmin241
Completed
Phase 3
Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- TarcevaMetastatic Colorectal Cancer
NCT00598156Lund University Hospital249
ACT: Avastin and Chemotherapy followed by... | Clinical Trial